SCHEMBL4880877

SCHEMBL4880877

O=C(NC1CCN(S(=O)(=O)c2ccc(Cl)cc2)CC1)C(O)C12CC3CC(CC(C3)C1)C2

nearest known ligand 0.57

Predicted protein targets (top 19)

geneUniProtsupporting neighboursconfidence
MEN1 O00255 2/20 0.57
KMT2A Q03164 2/20 0.57
LMNA P02545 5/20 0.54
HTT P42858 3/20 0.54
NPSR1 Q6W5P4 2/20 0.54
TSHR P16473 1/20 0.54
ALOX12 P18054 1/20 0.54
MAPT P10636 2/20 0.50
NPY1R P25929 1/20 0.50
NPY2R P49146 1/20 0.50
TGM2 P21980 2/20 0.46
ALDH1A1 P00352 3/20 0.46
CCR6 P51684 1/20 0.46
KDM4E B2RXH2 1/20 0.46
SMN1; SMN2 Q16637 1/20 0.46
CYP3A4 P08684 1/20 0.46
CNR1 P21554 1/20 0.46
POLB P06746 2/20 0.45
GAA P10253 1/20 0.45

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL4883298 0.89 LMNA (0.60) MEN1KMT2ALMNATGM2ALDH1A1
SCHEMBL14161818 0.89 KMT2A (0.50) MEN1KMT2ALMNAHTTNPSR1
SCHEMBL4882300 0.85 MEN1 (0.53) MEN1KMT2ALMNAHTTNPSR1
SCHEMBL4883119 0.84 TGM2 (0.53) MEN1KMT2ALMNAHTTNPSR1
SCHEMBL13651513 0.81 LMNA (0.67) MEN1KMT2ALMNAHTTNPSR1
SCHEMBL4881964 0.79 HTT (0.52) KMT2ALMNAHTTMAPTSMN1; SMN2
SCHEMBL14161819 0.76 KMT2A (0.47) MEN1KMT2ALMNAHTTNPSR1
SCHEMBL4874405 0.76 LMNA (0.48) MEN1KMT2ALMNATSHRALOX12
SCHEMBL4872365 0.75 LMNA (0.55) MEN1KMT2ALMNATGM2ALDH1A1
SCHEMBL14161900 0.75 LMNA (0.53) MEN1KMT2ALMNAHTTTSHR

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 3 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
US-20080200467-A1 SOLUBLE EPOXIDE HYDROLASE INHIBITORS ARETE THERAPEUTICS, INC. 2008-08-21 US disclosed
US-20080200467-A1 SOLUBLE EPOXIDE HYDROLASE INHIBITORS ARETE THERAPEUTICS, INC. 2008-08-21 US disclosed
US-20080200467-A1 SOLUBLE EPOXIDE HYDROLASE INHIBITORS ARETE THERAPEUTICS, INC. 2008-08-21 US disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20080200467-A1 SOLUBLE EPOXIDE HYDROLASE INHIBITORS EPHX1, EPHX2, NCEH1 MEN1 4501/4885KMT2A 2022/4885LMNA 1843/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.